Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

Tempus AI (TEM) announced multi-year, strategic collaborations with AstraZeneca (AZN) and Pathos AI, Inc., in which the companies will work ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's ...

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence (AI) to healthcare, has announced strategic collaborations with pharmaceutical giant AstraZeneca (LSE/STO ...

BTIG just kicked off coverage on Tempus AI (NASDAQ:TEM) with a Buy rating and a $60 price target suggesting nearly 48% upside from where the stock trades now. Analyst Mark Massaro called the ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation ...